Theradaptive, Inc.

Analysis

Theradaptive, Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is being reviewed within 1 distinct art unit. This indicates that the company's current prosecution activity is concentrated in a technical sector. The presence of the art unit suggests that the technology being patented falls within a specific classification at the patent office. This focus allows the company to direct its legal resources toward the point of contact within the patent office.

The busiest examiner for the company is AUDET, MAURY A, who is responsible for 1 pending office action. Since this examiner handles the pending matter, they are the individual currently evaluating the company's applications. For a practitioner, this means that the prosecution strategy is dependent on the feedback and requirements of the examiner within their assigned art unit. The lack of multiple pending actions simplifies the administrative tracking of the portfolio, as all communications are centralized. This concentration allows for a focused strategy when addressing the requirements of the art unit involved, ensuring that all responses are tailored to the specific expectations of the examiner.